Gut Microbes Linked to Cancer Outcomes and Chemotherapy Side Effects
Mayo Clinic researchers analyzed stool samples from 1,364 cancer patients and connected gut bacteria and microbial genes with treatment results and side effects. In colorectal cancer patients diagnosed at age 50 or younger, they found elevated lactate and higher levels of Veillonella parvula compared with older patients. Younger breast cancer patients had differences in 64 bacterial species, including Clostridium scindens, but brain cancer patients showed no similar age-related pattern.
Mayo Clinic's Cancer Microbiome cohort drew stool samples from 1,364 patients across 40 states, collected before treatment began at sites in Arizona, Florida and Minnesota. Linking those samples to medical records let researchers compare diagnoses with side effects and survival.
Colorectal cancer is rising roughly 3% yearly in adults 20 to 49, and breast cancer 1.4% yearly in women under 50, per the American Cancer Society. The team found 341 bacterial species tied to five cancer groups, though the work did not show these patterns cause early-onset disease.
If confirmed, these microbial signals could eventually inform how clinicians monitor or treat younger cancer patients, and might one day help predict who faces worse outcomes or harsher chemotherapy side effects. People diagnosed with colorectal or breast cancer before 50 — a growing group — may be most directly affected. Still, the study describes associations rather than causes, so any practical benefit, such as microbiome-guided screening or supportive care, remains speculative and would require validation before reaching patients.